Literature DB >> 4509638

Autonomous erythropoiesis during erythroblastic crisis of chronic myelocytic leukemia.

C H Srodes, E H Hyde, D R Boggs.   

Abstract

Two patients with chronic myelocytic leukemia who developed an erythroblastic rather than a myeloblastic phase were studied with respect to whether or not the megaloblastic erythropoiesis was subject to normal control mechanisms. After transfusion, no significant reduction was observed in the percentage of nucleated erythroid precursors or of proerythroblasts in marrow or in blood reticulocytes. In one of the two patients, ferrokinetics and urinary erythropoietin levels were studied and were also compatible with the conclusions that erythropoiesis was autonomous in this rare syndrome. Three patients with clinical pictures compatible with Di Guglielmo's syndrome were studied as controls. As has been reported previously, erythropoiesis in this syndrome appeared to be responsive to normal control mechanisms. These data suggest that these two clinically similar syndromes, erythroblastic crisis of chronic myelocytic leukemia and Di Guglielmo's syndrome may represent qualitatively different defects in hematopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4509638      PMCID: PMC302281          DOI: 10.1172/JCI107208

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  A CLINICAL STUDY OF TWENTY CASES OF ERYTHROLEUKEMIA (DI GUGLIELMO'S SYNDROME).

Authors:  R B SCOTT; R R ELLISON; A B LEY
Journal:  Am J Med       Date:  1964-08       Impact factor: 4.965

Review 2.  Chromosomal abnormalities in human neoplasia.

Authors:  A A Sandberg; D K Hossfeld
Journal:  Annu Rev Med       Date:  1970       Impact factor: 13.739

3.  The erythropoietin-hematocrit relationship in normal and polycythemic man: implications of marrow regulation.

Authors:  J W Adamson
Journal:  Blood       Date:  1968-10       Impact factor: 22.113

4.  Human leukemic cells: in vitro growth of colonies containing the Philadelphia (Ph) chromosome.

Authors:  P A Chervenick; L D Ellis; S F Pan; A L Lawson
Journal:  Science       Date:  1971-12-10       Impact factor: 47.728

5.  Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia.

Authors:  G P Canellos; V T DeVita; J Whang-Peng; P P Carbone
Journal:  Blood       Date:  1971-12       Impact factor: 22.113

6.  Acute myelogenous leukemia with compensatory but ineffective erythropoiesis: Di Guglielmo's syndrome.

Authors:  A D Schwartz; J H Zelson; H A Pearson
Journal:  J Pediatr       Date:  1970-10       Impact factor: 4.406

7.  Erythroid marrow regulation in myeloproliferative disease.

Authors:  A M Ganzoni; C Spycher Braendli; M Trachsler
Journal:  Helv Med Acta       Date:  1970-04

8.  Regulation of erythropoiesis in erythroleukemia.

Authors:  T G Gabuzda; H E Shute; A J Erslev
Journal:  Arch Intern Med       Date:  1969-01

9.  6-phosphogluconate dehydrogenase: hemizygous manifestation in a patient with leukemia.

Authors:  P J Fialkow; R Lisker; J Detter; E R Giblett; C Zavala
Journal:  Science       Date:  1969-01-10       Impact factor: 47.728

10.  Urinary excretion of erythropoietin in normal men and women.

Authors:  R Alexanian
Journal:  Blood       Date:  1966-09       Impact factor: 22.113

View more
  3 in total

1.  Megakaryoblastic transformation of chronic granulocytic leukaemia. An electron microscopy and cytochemial study.

Authors:  B Bain; D Catovsky; M O'Brien; A S Spiers; G H Richards
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

2.  Chronic lymphatic leukaemia terminating as erythroleukaemia.

Authors:  M M Al-Hilali; J O Edgcumbe; M V Joyner
Journal:  Postgrad Med J       Date:  1981-09       Impact factor: 2.401

3.  Erythroblastic transformation of chronic myeloid leukemia: hyperdiploid Ph1-positive karyotypes in primitive PAS-positive erythroblasts.

Authors:  B Pedersen; H Søndergaard-Petersen
Journal:  Blut       Date:  1981-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.